Opioid overdoses are spiking amid the pandemic – PBMs can help combat opioid abuse and misuse

November 24, 2020

The opioid epidemic in the United States is a crippling crisis with devastating impacts on public health and economic welfare. According to the Centers for Disease Control and Prevention, in 2018, more than one in five people filled an opioid prescription, and 40 people died daily after taking prescription opioids.

Since the start of the pandemic, data shows a concerning spike in opioid mortality rates across the country, with 40 states reporting increases. With the heightened uncertainty brought on by a pandemic, patients are facing new emotional, financial and social stressors that contribute to a spike in opioid overdoses. The increased reports of opioid abuse and misuse can also be attributed to pandemic-related barriers to health care, such as limited access to treatment facilities, lack of coverage and high cost for non-opioid pain treatments, insufficient access to telehealth, and prolonged opioid dependency with postponed elective surgeries.

For employers, the opioid epidemic leads to a ripple effect of economic and health concerns. While total costs from opioid abuse and misuse are estimated at $78.5 billion annually, a large, self-insured employer could spend an additional $14,810 for each covered employee who abuses opioids.

Read more by clicking the link to the full article below.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Navigating with a trusted partner

Now Available: 9th Annual Drug Trend Report

Our Drug Trend Report provides a clear view of the trends shaping pharmacy benefits today, along with strategies that are delivering real savings without compromising care.

Related blogs

Navigating Healthcare and Improving Outcomes

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

In this overview of our national Legal Ease webinar event, we highlight key federal and state developments shaping the conversation around PBM reform – and what they mean for your clients.  …

Navigating the Drug Supply Chain: What You Need to Know

Navigating the Drug Supply Chain: What You Need to Know

Before a prescription ever reaches a pharmacy counter, it has already moved through a complex ecosystem known as the drug supply chain. From manufacturers and wholesalers to pharmacy benefit managers (PBMs) and pharmacies, each entity plays a role in…

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

previous arrow
next arrow